US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

Equity Capital Markets

<ul>
<li>Medline’s IPO is poised to be 2025’s largest, with a potential $5.4bn raise, positioning it as a key bridge deal into the 2026 IPO pipeline.</li>
<li>Strong anchor demand and an oversubscribed book highlight investor appetite for scaled, mature healthcare platforms with durable cash flows.`</li>
<li>Proceeds will materially reduce leverage, supporting a more balanced capital structure and reinforcing Medline’s long-term investment appeal.</li>
</ul>


Medline’s IPO is poised to be 2025’s largest, with a potential $5.4bn raise, positioning it as a key bridge deal into the 2026 IPO pipeline.
Strong anchor demand and an oversubscribed book highlight investor appetite for scaled, mature healthcare platforms with durable cash flows.`
Proceeds will materially reduce leverage, supporting a more balanced capital structure and reinforcing Medline’s long-term investment appeal.


Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity

Infinity Natural Resources / Equity Capital Markets

<ul>
<li>Infinity Natural Resources (INR US)  came to market on January 31st pricing 13.25 million shares at $20.00 and opening at $22.16 for an 11.3% first-trade gain.</li>
<li>After peaking early in its first week, INR has experienced steady downward pressure. July was particularly brutal, with the stock declining 18%—its worst monthly performance since listing.</li>
<li>Infinity Natural Resources managed weakness from a broken IPO from its sector, Venture Global (VG). Six months later the sector winds have not calmed down.</li>
</ul>


Infinity Natural Resources (INR US)  came to market on January 31st pricing 13.25 million shares at $20.00 and opening at $22.16 for an 11.3% first-trade gain.
After peaking early in its first week, INR has experienced steady downward pressure. July was particularly brutal, with the stock declining 18%—its worst monthly performance since listing.
Infinity Natural Resources managed weakness from a broken IPO from its sector, Venture Global (VG). Six months later the sector winds have not calmed down.


Infinity Natural Resources (INR) Six Month Summary: Energy Sector Weakness Weighs on Stock Post-IPO

<ul>
<li>The company priced an upsized 12.0 million share offering at $17.00—above the initial range—and opened 29.4% higher at $22.00.</li>
<li>In March, amid broader sector weakness across the medical device space, the stock broke below its IPO price.</li>
<li>The company did report better than expected sales in its most recent quarterly report last week with guidance raised giving long term investors more confidence in its execution moving forward.</li>
</ul>


The company priced an upsized 12.0 million share offering at $17.00—above the initial range—and opened 29.4% higher at $22.00.
In March, amid broader sector weakness across the medical device space, the stock broke below its IPO price.
The company did report better than expected sales in its most recent quarterly report last week with guidance raised giving long term investors more confidence in its execution moving forward.


Beta Bionic Inc (BBNX) Six Month Summary: From Breakout to Breakdown

Venture Global LNG / Equity Capital Markets

<ul>
<li>Venture Global, Inc.’s IPO was one of the largest capital raises of the year, pulling in $1.75 billion through the sale of 70 million shares at $25.00 per share.</li>
<li>In the months following the IPO, the performance worsened. By April, Venture Global shares had plunged to a low of $6.75, marking a staggering 73% decline from its IPO price.</li>
<li>Regaining credibility will require not only strong quarterly results but also a sustained effort to rebuild institutional confidence.</li>
</ul>


Venture Global, Inc.’s IPO was one of the largest capital raises of the year, pulling in $1.75 billion through the sale of 70 million shares at $25.00 per share.
In the months following the IPO, the performance worsened. By April, Venture Global shares had plunged to a low of $6.75, marking a staggering 73% decline from its IPO price.
Regaining credibility will require not only strong quarterly results but also a sustained effort to rebuild institutional confidence.


Venture Global (VG) Six Month Summary: Failed IPO Shows How Fast Wall Street Love Can Fade

<ul>
<li>Figma is offering 36.9mm shares at $25.00-$28.00 equating to a market cap of $12.2bn-$13.65b and is scheduled to debut on July 31st.</li>
<li>They estimate their total revenue to increase by 39% to 41% for the three months ended June 30, 2025 compared to the three months ended June 30, 2024.</li>
<li>This company is highly regarded in the software sector and we believe that there will be ample interest in this IPO.</li>
</ul>


Figma is offering 36.9mm shares at $25.00-$28.00 equating to a market cap of $12.2bn-$13.65b and is scheduled to debut on July 31st.
They estimate their total revenue to increase by 39% to 41% for the three months ended June 30, 2025 compared to the three months ended June 30, 2024.
This company is highly regarded in the software sector and we believe that there will be ample interest in this IPO.


Figma Inc (FIG): High Profile Software IPO Sets Terms, Expecting Major Attention Next Week

United States

Venture Global LNG, Inc. operates as a producer of liquefied natural gas pipelines. The Company develops and constructs LNG export projects to provide clean, affordable energy to the world. Venture Global LNG serves worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Venture Global LNG (VG US)

Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity

Medline's upcoming IPO is set to be the largest of 2025, raising up to $5.4bn. Medline is a mature healthcare platforms with stable cash flows,...

IPO Boutique

Infinity Natural Resources (INR) Six Month Summary: Energy Sector Weakness Weighs on Stock Post-IPO

Infinity Natural Resources had a strong IPO debut but has since struggled, with July marking its worst monthly performance since listing due to...

IPO Boutique

Beta Bionic Inc (BBNX) Six Month Summary: From Breakout to Breakdown

Company prices upsized share offering above initial range, opens 29.4% higher. Stock broke below IPO price in March but recent quarterly may begin...

IPO Boutique

Venture Global (VG) Six Month Summary: Failed IPO Shows How Fast Wall Street Love Can Fade

Venture Global's $1.75 billion IPO was followed by a 73% decline in share price, now facing the challenge of rebuilding institutional confidence.

IPO Boutique

Figma Inc (FIG): High Profile Software IPO Sets Terms, Expecting Major Attention Next Week

Figma set to debut on July 31st with estimated revenue growth and high market cap, generating significant interest in IPO.

IPO Boutique

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Medline Inc. (MDLN): Largest Cash Raise IPO Since 2021's Rivian Brings End of Year Opportunity

​Medline's upcoming IPO is set to be the largest of 2025, raising up to $5.4bn. Medline is a mature healthcare platforms with stable cash flows,...

IPO Boutique

Infinity Natural Resources (INR) Six Month Summary: Energy Sector Weakness Weighs on Stock Post-IPO

​Infinity Natural Resources had a strong IPO debut but has since struggled, with July marking its worst monthly performance since listing due to...

IPO Boutique

Beta Bionic Inc (BBNX) Six Month Summary: From Breakout to Breakdown

​Company prices upsized share offering above initial range, opens 29.4% higher. Stock broke below IPO price in March but recent quarterly may begin...

IPO Boutique

Venture Global (VG) Six Month Summary: Failed IPO Shows How Fast Wall Street Love Can Fade

​Venture Global's $1.75 billion IPO was followed by a 73% decline in share price, now facing the challenge of rebuilding institutional confidence.

IPO Boutique

Figma Inc (FIG): High Profile Software IPO Sets Terms, Expecting Major Attention Next Week

​Figma set to debut on July 31st with estimated revenue growth and high market cap, generating significant interest in IPO.

IPO Boutique

Medline's upcoming IPO is set to be the largest of 2025, raising up to $5.4bn. Medline is a mature healthcare platforms with stable cash flows,...

Infinity Natural Resources had a strong IPO debut but has since struggled, with July marking its worst monthly performance since listing due to...

Company prices upsized share offering above initial range, opens 29.4% higher. Stock broke below IPO price in March but recent quarterly may begin...

Venture Global's $1.75 billion IPO was followed by a 73% decline in share price, now facing the challenge of rebuilding institutional confidence.

Figma set to debut on July 31st with estimated revenue growth and high market cap, generating significant interest in IPO.